Cover Image
市場調查報告書

全球核醫學設備市場趨勢,機會分析,市場佔有率與預測

Global Nuclear Medicine Equipment Market Insights, Opportunity Analysis, Market Shares and Forecast 2017 - 2023

出版商 Occams Business Research & Consulting Pvt. Ltd. 商品編碼 603559
出版日期 內容資訊 英文 190 Pages
商品交期: 請詢問到貨日
價格
Back to Top
全球核醫學設備市場趨勢,機會分析,市場佔有率與預測 Global Nuclear Medicine Equipment Market Insights, Opportunity Analysis, Market Shares and Forecast 2017 - 2023
出版日期: 2018年01月24日 內容資訊: 英文 190 Pages
簡介

本報告提供全球核醫學設備市場相關調查,彙整市場現狀與今後的預測,各市場區隔趨勢,各地區趨勢,及加入此市場的主要企業的簡介等資料。

第1章 簡介

第2章 市場概要

  • 全球市場:發展與變遷
  • 市場定義和範圍
  • 產業結構
  • 市場整體分析
  • 預測分析
  • 策略性分析
  • 競爭分析
  • 策略性建議與主要的結論

第3章 市場決策因素

  • 推動市場的要素
  • 阻礙市場的要素
  • 市場機會
  • 市場課題

第4章 市場區隔

  • 各產品
  • 各用途
  • 各終端用戶

第5章 競爭環境

  • 主要策略
    • 合併·收購
    • 合資企業
    • 產品上市
    • 聯盟

第6章 各地區分析

  • 支持決策的資料庫與預測技術
  • 比較分析
  • 機會矩陣
  • 各地區市場
    • 北美
    • 歐洲
    • 亞太地區
    • 其他各國

第7章 企業簡介

目錄
Product Code: HME-9050118

The global nuclear medicine equipment market is expected to rise with a CAGR of 3.5% during the forecast period 2016-2023. The key factors driving the market growth are the introduction of new and advanced products, public-private partnerships investments to modernize diagnostic imaging centers, advances in radiotracers, increasing prevalence of cancer and cardiac ailments and rising geriatric population.

Geographically, nuclear medicine equipment market is segmented into Asia Pacific, Europe, North America and ROW. North America is the leading region owing to the technological advancements in nuclear medicine equipment which has led to the increased adoption and growth of nuclear medicine in U.S. Additional factors such as highly developed healthcare infrastructure, emergence of new radiopharmaceuticals for therapeutics and diagnostics, etc. have propelled the North American market growth. However, Asia Pacific is expected to be the fastest growing region during the forecast period 2016-2023 owing to the increased research and development in the field of nuclear medicine in Asia Pacific countries including China, Japan, India, Australia, etc. Furthermore, increasing prevalence of cardiovascular and neurological diseases such as cancer, cardiovascular diseases, Alzheimer's, Parkinson's, etc., and rising geriatric population, growing healthcare expenditure, has led to surging demand for nuclear medicine equipment.

The global nuclear medicine equipment market is influenced by the presence of leading companies such as CMR Naviscan Corporation, GE Healthcare, Hitachi Medical Corporation, Medtronic Inc., Siemens AG etc. Merger and acquisition, product launch and joint venture are some of the crucial strategies adopted by the key market players to gain competitive advantage.

Global nuclear medicine equipment market report covers segmentation analysis of product, application and end user. Report further covers segments of product of nuclear medicine equipment which include Single Photon-Emission Computed Tomography (SPECT), Hybrid PET (Positron emission tomography) and Planar Scintigraphy. The SPECT product segment is further segmented into standalone SPECT and hybrid SPECT. SPECT is the leading product segment due to its low cost, high usage and better availability as compared to PET. Report further covers segments of applications of nuclear medicine equipment which includes cardiology, oncology, neurology and others. Cardiology is the leading application segment. Nuclear medicine is adopted in cardiology for the treatment of cardiomyopathy and Coronary Heart Disease (CHD). However, oncology is the fastest growing application segment owing to the increasing prevalence of cancer. According to American Cancer Society, approximately 13% of the deaths globally are due to cancer. Furthermore, screening methods for oncology using nuclear medicine equipment are expected to positively influence the market growth. The end users of nuclear medicine equipment include hospitals, imaging centers, academic and research centers and others.

Table of Contents

1. INTRODUCTION

  • 1.1. EXECUTIVE SUMMARY
  • 1.2. ESTIMATION METHODOLOGY

2. MARKET OVERVIEW

  • 2.1. GLOBAL NUCLEAR MEDICINE EQUIPMENT MARKET: EVOLUTION & TRANSITION
  • 2.2. MARKET DEFINITION & SCOPE
  • 2.3. INDUSTRY STRUCTURE
  • 2.4. REGULATOR FRAMEWORK
  • 2.5. TOTAL MARKET ANALYSIS
    • 2.5.1. TOP 5 FINDINGS
    • 2.5.2. TOP 5 OPPORTUNITY MARKETS
    • 2.5.3. TOP 5 COMPANIES
    • 2.5.4. TOP 3 COMPETITIVE STRATEGIES
  • 2.6. ESTIMATION ANALYSIS
  • 2.7. STRATEGIC ANALYSIS
    • 2.7.1. INVESTMENT VS. ADOPTION MODEL
    • 2.7.2. 360-DEGREE INDUSTRY ANALYSIS
    • 2.7.3. PORTERS 5 FORCE MODEL
    • 2.7.4. SEE-SAW ANALYSIS
    • 2.7.5. CONSUMER ANALYSIS AND KEY BUYING CRITERIA
  • 2.8. COMPETITIVE ANALYSIS
    • 2.8.1. KEY STRATEGIES & ANALYSIS
    • 2.8.2. MARKET SHARE ANALYSIS & TOP COMPANY ANALYSIS
  • 2.9. STRATEGIC RECOMMENDATIONS & KEY CONCLUSIONS
    • 2.9.1. INVESTMENT OPPORTUNITIES BY REGIONS
    • 2.9.2. OPPORTUNITIES IN EMERGING APPLICATIONS
    • 2.9.3. INVESTMENT OPPORTUNITY IN FASTEST GROWING SEGMENT

3. MARKET DETERMINANTS

  • 3.1. MARKET DRIVERS
    • 3.1.1. INTRODUCTION OF NEW AND ADVANCED PRODUCTS
    • 3.1.2. PUBLIC-PRIVATE PARTNERSHIP INVESTMENTS
    • 3.1.3. ADVANCES IN RADIOTRACERS
    • 3.1.4. INCREASING PREVALENCE OF CANCER AND CARDIAC AILMENTS
    • 3.1.5. INCREASING GERIATRIC POPULATION
  • 3.2. MARKET RESTRAINTS
    • 3.2.1. SHORTER HALF-LIFE OF RADIOPHARMACEUTICALS
    • 3.2.2. HIGH COST OF NUCLEAR MEDICINE EQUIPMENT
  • 3.3. MARKET OPPORTUNITIES
    • 3.3.1. STRONG PRODUCT PIPELINE
    • 3.3.2. HIGH DEMAND IN EMERGING MARKETS
  • 3.4. MARKET CHALLENGES
    • 3.4.1. INCREASING ADOPTION OF REFURBISHED DIAGNOSTIC IMAGING SYSTEMS
    • 3.4.2. HOSPITAL BUDGET CUTS

4. MARKET SEGMENTATION

  • 4.1. GLOBAL NUCLEAR MEDICINE EQUIPMENT MARKET BY PRODUCT
    • 4.1.1. MARKET DEFINITION AND SCOPE
    • 4.1.2. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
    • 4.1.3. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
    • 4.1.4. OPPORTUNITY MATRIX
    • 4.1.5. MARKET SEGMENTATION
      • 4.1.5.1. GLOBAL SINGLE PHOTON-EMISSION COMPUTED TOMOGRAPHY (SPECT) MARKET
        • 4.1.5.1.1. ADOPTION SCENARIO & MARKET DETERMINANTS
        • 4.1.5.1.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
        • 4.1.5.1.3. KEY PLAYERS & KEY PRODUCTS
        • 4.1.5.1.4. KEY CONCLUSIONS
      • 4.1.5.2. GLOBAL HYBRID PET SYSTEMS MARKET
        • 4.1.5.2.1. ADOPTION SCENARIO & MARKET DETERMINANTS
        • 4.1.5.2.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
        • 4.1.5.2.3. KEY PLAYERS & KEY PRODUCTS
        • 4.1.5.2.4. KEY CONCLUSIONS
      • 4.1.5.3. GLOBAL PLANAR SCINTIGRAPHY MARKET
        • 4.1.5.3.1. ADOPTION SCENARIO & MARKET DETERMINANTS
        • 4.1.5.3.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
        • 4.1.5.3.3. TOP PLAYERS & KEY PRODUCTS
        • 4.1.5.3.4. KEY CONCLUSIONS
  • 4.2. GLOBAL NUCLEAR MEDICINE EQUIPMENT MARKET BY APPLICATION
    • 4.2.1. MARKET DEFINITION AND SCOPE
    • 4.2.2. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
    • 4.2.3. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
    • 4.2.4. OPPORTUNITY MATRIX
    • 4.2.5. MARKET SEGMENTATION
      • 4.2.5.1. GLOBAL CARDIOLOGY MARKET
        • 4.2.5.1.1. ADOPTION SCENARIO & MARKET DETERMINANTS
        • 4.2.5.1.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
        • 4.2.5.1.3. KEY PLAYERS & KEY PRODUCTS
        • 4.2.5.1.4. KEY CONCLUSIONS
      • 4.2.5.2. GLOBAL ONCOLOGY MARKET
        • 4.2.5.2.1. ADOPTION SCENARIO & MARKET DETERMINANTS
        • 4.2.5.2.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
        • 4.2.5.2.3. KEY PLAYERS & KEY PRODUCTS
        • 4.2.5.2.4. KEY CONCLUSIONS
      • 4.2.5.3. GLOBAL NEUROLOGY MARKET
        • 4.2.5.3.1. ADOPTION SCENARIO & MARKET DETERMINANTS
        • 4.2.5.3.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
        • 4.2.5.3.3. KEY PLAYERS & KEY PRODUCTS
        • 4.2.5.3.4. KEY CONCLUSIONS
      • 4.2.5.4. GLOBAL OTHER APPLICATIONS MARKET
        • 4.2.5.4.1. ADOPTION SCENARIO & MARKET DETERMINANTS
        • 4.2.5.4.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
        • 4.2.5.4.3. TOP PLAYERS & KEY PRODUCTS
        • 4.2.5.4.4. KEY CONCLUSIONS
  • 4.3. GLOBAL NUCLEAR MEDICINE EQUIPMENT MARKET BY END USER
    • 4.3.1. MARKET DEFINITION AND SCOPE
    • 4.3.2. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
    • 4.3.3. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
    • 4.3.4. OPPORTUNITY MATRIX
    • 4.3.5. MARKET SEGMENTATION
      • 4.3.5.1. GLOBAL HOSPITALS MARKET
        • 4.3.5.1.1. ADOPTION SCENARIO & MARKET DETERMINANTS
        • 4.3.5.1.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
        • 4.3.5.1.3. KEY PLAYERS & KEY PRODUCTS
        • 4.3.5.1.4. KEY CONCLUSIONS
      • 4.3.5.2. GLOBAL IMAGING CENTERS MARKET
        • 4.3.5.2.1. ADOPTION SCENARIO & MARKET DETERMINANTS
        • 4.3.5.2.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
        • 4.3.5.2.3. KEY PLAYERS & KEY PRODUCTS
        • 4.3.5.2.4. KEY CONCLUSIONS
      • 4.3.5.3. GLOBAL ACADEMIC AND RESEARCH CENTERS MARKET
        • 4.3.5.3.1. ADOPTION SCENARIO & MARKET DETERMINANTS
        • 4.3.5.3.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
        • 4.3.5.3.3. KEY PLAYERS & KEY PRODUCTS
        • 4.3.5.3.4. KEY CONCLUSIONS
      • 4.3.5.4. GLOBAL OTHER END USERS MARKET
        • 4.3.5.4.1. ADOPTION SCENARIO & MARKET DETERMINANTS
        • 4.3.5.4.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
        • 4.3.5.4.3. KEY PLAYERS & KEY PRODUCTS
        • 4.3.5.4.4. KEY CONCLUSIONS

5. COMPETITIVE LANDSCAPE

  • 5.1. KEY STRATEGIES
    • 5.1.1. LIST OF MERGERS AND ACQUISITION
    • 5.1.2. LIST OF JOINT VENTURES
    • 5.1.3. LIST OF PRODUCT LAUNCHES
    • 5.1.4. LIST OF PARTNERSHIP

6. GEOGRAPHIC ANALYSIS

  • 6.1. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
  • 6.2. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
  • 6.3. OPPORTUNITY MATRIX
  • 6.4. GLOBAL NUCLEAR MEDICINE EQUIPMENT MARKET BY REGION 2014-2023 ($ MILLION)
    • 6.4.1. NORTH AMERICA
      • 6.4.1.1. INDUSTRY ANALYSIS 2014-2023 ($ MILLION)
      • 6.4.1.2. TOP COUNTRY ANALYSIS
        • 6.4.1.2.1. U.S.
          • 6.4.1.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
          • 6.4.1.2.1.2. KEY PLAYERS & KEY PRODUCTS
          • 6.4.1.2.1.3. KEY CONCLUSIONS
        • 6.4.1.2.2. CANADA
          • 6.4.1.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023
          • 6.4.1.2.2.2. KEY PLAYERS & KEY PRODUCTS
          • 6.4.1.2.2.3. KEY CONCLUSIONS
    • 6.4.2. EUROPE
      • 6.4.2.1. INDUSTRY ANALYSIS 2014-2023 ($ MILLION)
      • 6.4.2.2. TOP COUNTRY ANALYSIS
        • 6.4.2.2.1. UK
          • 6.4.2.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023
          • 6.4.2.2.1.2. KEY PLAYERS & KEY PRODUCTS
          • 6.4.2.2.1.3. KEY CONCLUSIONS
        • 6.4.2.2.2. FRANCE
          • 6.4.2.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023
          • 6.4.2.2.2.2. KEY PLAYERS & KEY PRODUCTS
          • 6.4.2.2.2.3. KEY CONCLUSIONS
        • 6.4.2.2.3. GERMANY
          • 6.4.2.2.3.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023
          • 6.4.2.2.3.2. KEY PLAYERS & KEY PRODUCTS
          • 6.4.2.2.3.3. KEY CONCLUSIONS
        • 6.4.2.2.4. SPAIN
          • 6.4.2.2.4.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023
          • 6.4.2.2.4.2. KEY PLAYERS & KEY PRODUCTS
          • 6.4.2.2.4.3. KEY CONCLUSIONS
        • 6.4.2.2.5. REST OF EUROPE
          • 6.4.2.2.5.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023
          • 6.4.2.2.5.2. KEY PLAYERS & KEY PRODUCTS
          • 6.4.2.2.5.3. KEY CONCLUSIONS
    • 6.4.3. ASIA PACIFIC
      • 6.4.3.1. INDUSTRY ANALYSIS 2014-2023 ($ MILLION)
      • 6.4.3.2. TOP COUNTRY ANALYSIS
        • 6.4.3.2.1. CHINA
          • 6.4.3.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023
          • 6.4.3.2.1.2. KEY PLAYERS & KEY PRODUCTS
          • 6.4.3.2.1.3. KEY CONCLUSIONS
        • 6.4.3.2.2. INDIA
          • 6.4.3.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023
          • 6.4.3.2.2.2. KEY PLAYERS & KEY PRODUCTS
          • 6.4.3.2.2.3. KEY CONCLUSIONS
        • 6.4.3.2.3. JAPAN
          • 6.4.3.2.3.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023
          • 6.4.3.2.3.2. KEY PLAYERS & KEY PRODUCTS
          • 6.4.3.2.3.3. KEY CONCLUSIONS
        • 6.4.3.2.4. AUSTRALIA
          • 6.4.3.2.4.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023
          • 6.4.3.2.4.2. KEY PLAYERS & KEY PRODUCTS
          • 6.4.3.2.4.3. KEY CONCLUSIONS
        • 6.4.3.2.5. REST OF ASIA PACIFIC
          • 6.4.3.2.5.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023
          • 6.4.3.2.5.2. KEY PLAYERS & KEY PRODUCTS
          • 6.4.3.2.5.3. KEY CONCLUSIONS
    • 6.4.4. ROW
      • 6.4.4.1. INDUSTRY ANALYSIS 2014-2023 ($ MILLION)
      • 6.4.4.2. TOP COUNTRY ANALYSIS
        • 6.4.4.2.1. LATIN AMERICA
          • 6.4.4.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023
          • 6.4.4.2.1.2. KEY PLAYERS & KEY PRODUCTS
          • 6.4.4.2.1.3. KEY CONCLUSIONS
        • 6.4.4.2.2. MIDDLE EAST & AFRICA
          • 6.4.4.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023
          • 6.4.4.2.2.2. KEY PLAYERS & KEY PRODUCTS
          • 6.4.4.2.2.3. KEY CONCLUSIONS

7. COMPANY PROFILES

  • 7.1. CMR NAVISCAN CORPORATION (U.S.)
    • 7.1.1. OVERVIEW
    • 7.1.2. PRODUCT PORTFOLIO
    • 7.1.3. STRATEGIC INITIATIVES
    • 7.1.4. SCOT ANALYSIS
    • 7.1.5. STRATEGIC ANALYSIS
  • 7.2. DDD-DIAGNOSTIC A/S (DENMARK)
    • 7.2.1. OVERVIEW
    • 7.2.2. PRODUCT PORTFOLIO
    • 7.2.3. STRATEGIC INITIATIVES
    • 7.2.4. SCOT ANALYSIS
    • 7.2.5. STRATEGIC ANALYSIS
  • 7.3. DIGIRAD CORPORATION (U.S.)
    • 7.3.1. OVERVIEW
    • 7.3.2. PRODUCT PORTFOLIO
    • 7.3.3. STRATEGIC INITIATIVES
    • 7.3.4. SCOT ANALYSIS
    • 7.3.5. STRATEGIC ANALYSIS
  • 7.4. FUJIFILM HOLDINGS (JAPAN)
    • 7.4.1. OVERVIEW
    • 7.4.2. PRODUCT PORTFOLIO
    • 7.4.3. STRATEGIC INITIATIVES
    • 7.4.4. SCOT ANALYSIS
    • 7.4.5. STRATEGIC ANALYSIS
  • 7.5. GE HEALTHCARE (UK)
    • 7.5.1. OVERVIEW
    • 7.5.2. PRODUCT PORTFOLIO
    • 7.5.3. STRATEGIC INITIATIVES
    • 7.5.4. SCOT ANALYSIS
    • 7.5.5. STRATEGIC ANALYSIS
  • 7.6. HITACHI MEDICAL CORPORATION (JAPAN)
    • 7.6.1. OVERVIEW
    • 7.6.2. PRODUCT PORTFOLIO
    • 7.6.3. STRATEGIC INITIATIVES
    • 7.6.4. SCOT ANALYSIS
    • 7.6.5. STRATEGIC ANALYSIS
  • 7.7. HOLOGIC (U.S.)
    • 7.7.1. OVERVIEW
    • 7.7.2. PRODUCT PORTFOLIO
    • 7.7.3. STRATEGIC INITIATIVES
    • 7.7.4. SCOT ANALYSIS
    • 7.7.5. STRATEGIC ANALYSIS
  • 7.8. MEDISO MEDICAL IMAGING SYSTEMS LTD (HUNGARY)
    • 7.8.1. OVERVIEW
    • 7.8.2. PRODUCT PORTFOLIO
    • 7.8.3. STRATEGIC INITIATIVES
    • 7.8.4. SCOT ANALYSIS
    • 7.8.5. STRATEGIC ANALYSIS
  • 7.9. MEDTRONIC INC. (U.S.)
    • 7.9.1. OVERVIEW
    • 7.9.2. PRODUCT PORTFOLIO
    • 7.9.3. STRATEGIC INITIATIVES
    • 7.9.4. SCOT ANALYSIS
    • 7.9.5. STRATEGIC ANALYSIS
  • 7.10. NEUSOFT MEDICAL SYSTEMS CO. LTD. (CHINA)
    • 7.10.1. OVERVIEW
    • 7.10.2. PRODUCT PORTFOLIO
    • 7.10.3. STRATEGIC INITIATIVES
    • 7.10.4. SCOT ANALYSIS
    • 7.10.5. STRATEGIC ANALYSIS
  • 7.11. PHILIPS HEALTHCARE (NETHERLANDS)
    • 7.11.1. OVERVIEW
    • 7.11.2. PRODUCT PORTFOLIO
    • 7.11.3. STRATEGIC INITIATIVES
    • 7.11.4. SCOT ANALYSIS
    • 7.11.5. STRATEGIC ANALYSIS
  • 7.12. SHIMADZU CORPORATION (JAPAN)
    • 7.12.1. OVERVIEW
    • 7.12.2. PRODUCT PORTFOLIO
    • 7.12.3. STRATEGIC INITIATIVES
    • 7.12.4. SCOT ANALYSIS
    • 7.12.5. STRATEGIC ANALYSIS
  • 7.13. SIEMENS AG (GERMANY)
    • 7.13.1. OVERVIEW
    • 7.13.2. PRODUCT PORTFOLIO
    • 7.13.3. STRATEGIC INITIATIVES
    • 7.13.4. SCOT ANALYSIS
    • 7.13.5. STRATEGIC ANALYSIS
  • 7.14. SURGICEYE GMBH (GERMANY)
    • 7.14.1. OVERVIEW
    • 7.14.2. PRODUCT PORTFOLIO
    • 7.14.3. STRATEGIC INITIATIVES
    • 7.14.4. SCOT ANALYSIS
    • 7.14.5. STRATEGIC ANALYSIS
  • 7.15. TOSHIBA MEDICAL SYSTEMS CORPORATION (JAPAN)
    • 7.15.1. OVERVIEW
    • 7.15.2. PRODUCT PORTFOLIO
    • 7.15.3. STRATEGIC INITIATIVES
    • 7.15.4. SCOT ANALYSIS
    • 7.15.5. STRATEGIC ANALYSIS

LIST OF TABLES

  • 1. GLOBAL NUCLEAR MEDICINE EQUIPMENT MARKET BY PRODUCT 2014-2023 ($ MILLION)
  • 2. GLOBAL SINGLE PHOTON-EMISSION COMPUTED TOMOGRAPHY (SPECT) MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
  • 3. GLOBAL HYBRID PET MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
  • 4. GLOBAL PLANAR SCINTIGRAPHY MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
  • 5. GLOBAL NUCLEAR MEDICINE EQUIPMENT MARKET BY APPLICATION 2014-2023 ($ MILLION)
  • 6. GLOBAL CARDIOLOGY MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
  • 7. GLOBAL ONCOLOGY MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
  • 8. GLOBAL NEUROLOGY MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
  • 9. GLOBAL OTHER APPLICATIONS MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
  • 10. GLOBAL NUCLEAR MEDICINE EQUIPMENT MARKET BY END USER 2014-2023 ($ MILLION)
  • 11. GLOBAL HOSPITALS MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
  • 12. GLOBAL IMAGING CENTERS MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
  • 13. GLOBAL ACADEMIC AND RESEARCH CENTERS MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
  • 14. GLOBAL OTHER END USER MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
  • 15. NORTH AMERICA NUCLEAR MEDICINE EQUIPMENT MARKET 2014-2023 ($ MILLION)
  • 16. EUROPE NUCLEAR MEDICINE EQUIPMENT MARKET 2014-2023 ($ MILLION)
  • 17. ASIA PACIFIC NUCLEAR MEDICINE EQUIPMENT MARKET 2014-2023 ($ MILLION)
  • 18. REST OF THE WORLD NUCLEAR MEDICINE EQUIPMENT MARKET 2014-2023 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL SINGLE PHOTON-EMISSION COMPUTED TOMOGRAPHY (SPECT) MARKET 2014-2023 ($ MILLION)
  • 2. GLOBAL HYBRID PET MARKET 2014-2023 ($ MILLION)
  • 3. GLOBAL PLANAR SCINTIGRAPHY MARKET 2014-2023 ($ MILLION)
  • 4. GLOBAL CARDIOLOGY MARKET 2014-2023 ($ MILLION)
  • 5. GLOBAL ONCOLOGY MARKET 2014-2023 ($ MILLION)
  • 6. GLOBAL NEUROLOGY MARKET 2014-2023 ($ MILLION)
  • 7. GLOBAL OTHER APPLICATIONS MARKET 2014-2023 ($ MILLION)
  • 8. GLOBAL HOSPITALS MARKET 2014-2023 ($ MILLION)
  • 9. GLOBAL IMAGING CENTERS MARKET 2014-2023 ($ MILLION)
  • 10. GLOBAL ACADEMIC AND RESEARCH CENTERS MARKET 2014-2023 ($ MILLION)
  • 11. GLOBAL OTHER END USER MARKET 2014-2023 ($ MILLION)
  • 12. UNITED STATES (U.S.) NUCLEAR MEDICINE EQUIPMENT MARKET 2014-2023 ($ MILLION)
  • 13. CANADA NUCLEAR MEDICINE EQUIPMENT MARKET 2014-2023 ($ MILLION)
  • 14. UNITED KINGDOM (UK) NUCLEAR MEDICINE EQUIPMENT MARKET 2014-2023 ($ MILLION)
  • 15. FRANCE NUCLEAR MEDICINE EQUIPMENT MARKET 2014-2023 ($ MILLION)
  • 16. GERMANY NUCLEAR MEDICINE EQUIPMENT MARKET 2014-2023 ($ MILLION)
  • 17. SPAIN NUCLEAR MEDICINE EQUIPMENT MARKET 2014-2023 ($ MILLION)
  • 18. ROE NUCLEAR MEDICINE EQUIPMENT MARKET 2014-2023 ($ MILLION)
  • 19. INDIA NUCLEAR MEDICINE EQUIPMENT MARKET 2014-2023 ($ MILLION)
  • 20. CHINA NUCLEAR MEDICINE EQUIPMENT MARKET 2014-2023 ($ MILLION)
  • 21. JAPAN NUCLEAR MEDICINE EQUIPMENT MARKET 2014-2023 ($ MILLION)
  • 22. AUSTRALIA NUCLEAR MEDICINE EQUIPMENT MARKET 2014-2023 ($ MILLION)
  • 23. ROAPAC NUCLEAR MEDICINE EQUIPMENT MARKET 2014-2023 ($ MILLION)
  • 24. LATIN AMERICA NUCLEAR MEDICINE EQUIPMENT MARKET 2014-2023 ($ MILLION)
  • 25. MENA NUCLEAR MEDICINE EQUIPMENT MARKET 2014-2023 ($ MILLION)
Back to Top